Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

101.90USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$101.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
487,526
52-wk High
$104.42
52-wk Low
$75.84

Select another date:

Thu, May 24 2018

FDA approves BioMarin rare metabolic disorder drug, shares rise

U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.

FDA approves BioMarin rare metabolic disorder drug, shares rise

May 24 U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.

BRIEF-Biomarin Announces First Patient Dosed In Phase 1/2 Study Of Treatment For Type of Hemophilia A

* BIOMARIN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 STUDY EVALUATING VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY IN SEVERE HEMOPHILIA A PATIENTS WITH PRE-EXISTING AAV5 ANTIBODIES Source text for Eikon: Further company coverage:

BRIEF-Biomarin Pharmaceutical Q1 GAAP Loss Per Share $0.26

* Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION

BRIEF-Biomarin Pharmaceutical Reports Q1 Loss Per Share Of $0.25

* Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION

BRIEF-Biomarin Pharma CEO's 2017 Compensation Was $15.9 Million

* BIOMARIN PHARMACEUTICAL INC SAYS CEO JEAN-JACQUES BIENAIMÉ'S 2017 TOTAL COMPENSATION WAS $15.9 MILLION VERSUS $16.9 MILLION IN 2016 – SEC FILING

BRIEF-European Medicines Agency Accepts Biomarin's Marketing Application For Pegvaliase

* EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS BIOMARIN'S MARKETING APPLICATION FOR PEGVALIASE MAA FOR TREATMENT OF PHENYLKETONURIA (PKU)

BRIEF-BioMarin Q4 GAAP Loss Per Share $0.30

* BIOMARIN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Select another date: